It's time for Apple (NASDAQ: AAPL ) to start an iPhone family. Instead of releasing one model per year, and moving older iPhones to successively lower price points, Apple is widely expected to launch multiple models later this year for the first time in the product's history.
Assuming that the iPhone maker releases a mid-range iPhone alongside a new flagship, what happens to the lineup?
The mid-range model that is being referred to casually as the "iPhone Lite" that's made out of polycarbonate is expected to price between $350 and $400 without carrier subsidies. That would give the device a better chance at penetrating emerging markets, particularly those that don't utilize the subsidy model. However, within subsidized markets, that retail price tag is less than the estimated $425 subsidy that Apple currently fetches, which implies that it would displace the iPhone 4 as the new free-on-contract iPhone.
If Apple were to still partially implement its previous strategy of moving older models down, it could then keep the iPhone 5 at the $100 subsidized price point, while the updated flagship "iPhone 5S" would start at $200 on contract. That seems to be the most logical strategy that covers all the relevant subsidized price points, which implies that Apple may discontinue the iPhone 4 and iPhone 4S.
Best China Stocks To Own For 2015: Magellan Health Services Inc.(MGLN)
Magellan Health Services, Inc. engages in the specialty managed healthcare business in the United States. The company, through its contracted network of third-party treatment providers, offers managed behavioral healthcare services, including outpatient programs, such as counseling or therapy; intermediate care programs comprising intensive outpatient programs and partial hospitalization services; and inpatient treatment and crisis intervention services. It also provides radiology benefits management services, such as the delivery of diagnostic imaging and other therapeutic services through contracts with health plans and insurance companies, and governmental agencies. In addition, the company offers specialty pharmaceutical management services, including contracting and formulary optimization programs; specialty pharmaceutical dispensing operations; and medical pharmacy management programs. Its specialty pharmaceutical management services are provided under contracts with health plans, insurance companies, employers, and governmental agencies to manage specialty drugs used in the treatment of conditions, such as cancer, multiple sclerosis, hemophilia, infertility, rheumatoid arthritis, chronic forms of hepatitis, and other diseases. Further, the company provides Medicaid administration services comprising pharmacy point-of-sale claims processing systems and administration, drug utilization review, clinical prior authorization, utilization and formulary management services, preferred drug list programs, maximum allowable cost programs, and drug rebate program services under contracts with health plans and public sector healthcare clients for Medicaid and other program recipients. It serves health plans, insurance companies, employers, labor unions, and various governmental agencies. Magellan Health Services, Inc. was founded in 1969 and is based in Avon, Connecticut.
Advisors' Opinion:- [By Jake L'Ecuyer]
Magellan Health Services (NASDAQ: MGLN) shares tumbled 3.53 percent to $58.98 after the company reported a 50% drop in its fourth-quarter earnings.
5 Best High Tech Stocks To Watch Right Now: Greengro Technologies Inc (GRNH)
GreenGro Technologies Inc., formerly Authoriszor Inc., provides management services for the planning, construction, staffing and operation of medical marijuana dispensaries, and nurseries on behalf of non-profit patient co-operatives. Through long term contracts, the Company operates non-profit centers, returning all unused patient contributions, on a pro-rata basis to each co-op member in the form of additional product. In February 2010, Authoriszor Inc. completed the acquisition of GreenGro Technologies, Inc., and CannovaHealth, a clinic management company. In September 2011, the Company acquired Vertical Hydrogarden, Inc.
Medical marijuana (medical cannabis) is an alternative method to other forms of medication used to manage or alleviate pain without the undo side-effects caused by the prescription medication being used to treat an illness. The Company stands ready to assist in patient care co-operatives throughout the United States.
Advisors' Opinion:- [By Dan Burrows]
But it doesn’t end there. Investors should run away from all OTC marijuana stocks, including Medical Marijuana (MJNA), Cannabis Science (CBIS), CannaVest (CANV), MediSwipe (MWIP) and GreenGro Technologies (GRNH). As the SEC warns:
- [By James E. Brumley]
If it seems like the buzz surrounding marijuana stocks like Medical Marijuana Inc. (OTCMKTS:MJNA), Hemp, Inc. (OTCMKTS:HEMP), and GreenGro Technologies, Inc. (OTCMKTS:GRNH) has been a little louder than usual the last few days, you're not crazy - it has been louder, and particularly bullish. GRNH shares advanced 37% in December. HEMP is up 166% for the past two weeks. MJNA has jumped 47% in just the past couple of days. Well, as it turns out, it's not just mere coincidence that GreenGro Technologies, Hemp, Medical Marijuana, and a bunch of other cannabis-related names have perked up of late. And, odds are pretty good they'll all continue to do well (even of the pace slows a bit) in 2014.
- [By Ben Levisohn]
But, as the Huffington Post points out, most of the companies that stand to benefit are very small–they make micro caps look big–trade over the counter–good bye liquidity. That includes transaction-processing company MediSwipe (MWIPD), GreenGro Technologies (GRNH) Medbox (MDBX), which makes dispenser for high-risk drugs, and GW Pharmaceuticals (GWPRF).
- [By Dan Burrows]
MediSwipe (MWIP) has tripled, with MWIP stock up 200%. Cannabis Science (CBIS) is closing in on quadrupling, as CBIS stock gained 273%. And GreenGro Technologies (GRNH)? Brace yourself, because GRNH stock is up over 1,000% … including an 18% so far today.
5 Best High Tech Stocks To Watch Right Now: IsoRay Inc (ISR)
IsoRay, Inc. (IsoRay), incorporated on June 15, 2004, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. IsoRay International LLC (International) is a wholly owned subsidiary of the Company. IsoRay obtained clearance from the Food and Drug Association (FDA) for treatment for all solid tumor applications using Cesium-131. Such applications include prostate cancer; ocular melanoma; head, neck and lung tumors; breast cancer; liver cancer; brain cancer; colorectal cancer; gynecological cancer; esophageal cancer, and pancreatic cancer. The seed may be used in surface, interstitial and intracavity applications for tumors with known radio sensitivity. The Company has an existing distribution agreement with UralDial LLC (UralDial) that allows UralDial to distribute Proxcelan Cs-131 brachytherapy seeds in Russia. The Company, through UralDial, has regulatory approval to sell Cs-131 seeds in Russia.
IsoRay markets the Proxcelan Cesium-131 brachytherapy seed for the treatment of prostate cancer; lung cancer; ocular melanoma; head and neck cancers; colorectal cancer, brain cancer; and gynecological cancer. The Company focuses to market Cesium-131 for the treatment of other malignant disease, such as breast cancer, in the near future through the use of existing technologies that have received FDA-clearance. Cesium-131 is a radioactive isotope that can be produced by the neutron bombardment of Barium-130 (Ba-130). When placed into a nuclear reactor and exposed to a flux of neutrons, Ba-130 becomes Ba-131, the radioactive material that is the parent isotope of Cesium-131. The radioactive isotope Cesium-131 is normally produced by placing a quantity of stable non-radioactive barium (ideally barium enriched in isotope Ba-130) into the neutron flux of a nuclear reactor. The irradiation process converts a small fraction of this material into a radioactive form of barium (Ba-131). The Ba-131 decays by electron capture to the ! radioactive isotope of interest (Cesium-131).
As of June 30, 2011, IsoRay had agreements with several independent radiopharmacies to assay, preload, and sterilize loose seeds. During the fiscal year ended June 30, 2011, the Company loaded approximately 90% of Mick cartridges in the Company's own facility, which accounted for approximately 61% of seeds sold. Approximately 33% of seeds sold are strand configurations, including strands preloaded in needles and the remaining 6% of seeds are sold as loose seeds.
Advisors' Opinion:- [By James E. Brumley]
I hate to be the one to say I told you so, but, I told you so. Back on February 26th I suggested IsoRay, Inc. (NYSEMKT:ISR) shares were a budding breakout play. The 48% rally that's played out for ISR in the meantime unfurled right on cue. While overbought in the very short run, this small cap stock looks like it's earning the right to be compared to the likes of bigger brothers in the cancer-treatment space... names like Roche Holding Ltd. (OTCMKTS:RHHBY) or Theragenics Corporation (NYSE:TGX).
- [By Vanina Egea]
Strengthening portfolio and business stability is to be reinforced by the introduction of new products. Last December, Textron announced the successful first flight of the Scorpion Intelligence, Surveillance and Reconnaissance (ISR)/Strike aircraft. ��he Scorpion compares very favorably to more costly aircraft currently used for low-threat missions,��pilot Dan Hinson said. The new product is expected to accommodate the budget constraints and shifting mission requirements of the US Department of Defense. The same department has granted the firm an additional contract worth $22.5 million to "deprocess" Mobile Strike Force vehicles and train the Afghan Army.
- [By James E. Brumley]
Ugh. It's fun to be right about a stock, but it's exhausting to be too right, too fast. Case in Point? IsoRay, Inc. (NYSE: ISR). Yours truly posted some bullish comments on ISR just a couple of days ago, explaining how that day's move above a key ceiling meant a new bull trend was underway, and more gains from that price would be far easier to muster. Well, good news for those who heeded the advice - IsoRay shares are up 44% today.
5 Best High Tech Stocks To Watch Right Now: Newcrest Mining Ltd (NCM)
Newcrest Mining Limited (Newcrest) is a gold, copper and silver producer that has operations and exploration projects in Australia, the Pacific region, Asia and West Africa. The Company�� segments include Cadia Valley, Telfer, Gosowong, Lihir, Hidden Valley JV, West Africa (includes Bonikro operations and exploration and evaluation activities in Cote d��voire) and Exploration and Other. Exploration and Other mainly consists of projects in the exploration, evaluation and feasibility phase and includes Namosi in Fiji, Wafi Golpu in Papua New Guinea (PNG), and Marsden and O��allaghans in Australia. Cadia Valley Operations (CVO) is a gold mining operation and is 100% owned by Newcrest. It is located approximately 25 kilometers from the city of Orange in central west New South Wales and is 250 kilometers west of Sydney. Advisors' Opinion:- [By Jasmine Ng]
Newcrest Mining Ltd. (NCM), Australia�� biggest gold producer, sank 6.7 percent as bullion traded near a five-month low. Hyundai Motor Co., South Korea�� top carmaker, lost 4.2 percent as November sales fell. Sekisui Chemical Co. surged 7.5 percent in Tokyo on a report it developed a material that triples the capacity of electric-vehicle batteries.
No comments:
Post a Comment